US20050089493A1 - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
US20050089493A1
US20050089493A1 US10/990,819 US99081904A US2005089493A1 US 20050089493 A1 US20050089493 A1 US 20050089493A1 US 99081904 A US99081904 A US 99081904A US 2005089493 A1 US2005089493 A1 US 2005089493A1
Authority
US
United States
Prior art keywords
peptide
spermine
based surfactant
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/990,819
Inventor
Patrick Camilleri
Philippe Guedat
Anthony Kirby
Andreas Kremer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Cambridge University Technical Services Ltd CUTS
Original Assignee
SmithKline Beecham Ltd
Cambridge University Technical Services Ltd CUTS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, Cambridge University Technical Services Ltd CUTS filed Critical SmithKline Beecham Ltd
Priority to US10/990,819 priority Critical patent/US20050089493A1/en
Publication of US20050089493A1 publication Critical patent/US20050089493A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09Diamines
    • C07C211/11Diaminopropanes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069Ser-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Definitions

  • Surfactants are substances that markedly affect the surface properties of a liquid, even at low concentrations. For example surfactants will significantly reduce surface tension when dissolved in water or aqueous solutions and will reduce interfacial tension between two liquids or a liquid and a solid. This property of surfactant molecules has been widely exploited in industry, particularly in the detergent and oil industries. In the 1970s a new class of surfactant molecule was reported, characterised by two hydrophobic chains with polar heads which are linked by a hydrophobic bridge (excellentga, Y et al., Kolloidn. Zh. 36, 649, 1974). These molecules, which have been termed “gemini” (Menger, F M and Littau, C A, J. Am. Chem. Soc. 113, 1451, 1991), have very desirable properties over their monomeric equivalents. For example they are highly effective in reducing interfacial tension between oil and water based liquids and have a very low critical micelle concentration.
  • the bis-phthalimide (400 mg, 0.48 mmol) was dissolved in 20 ml of MeOH, hydrazine monohydrate 0.4 ml was added and the mixture was refluxed 6H. Solvent was removed, and the crude redissolved in MeOH (20 ml) and 2 ml of concentrated HCl was added. The mixture was refluxed for 30 min, and solvent was removed. The residue was dissolved in aqueous NaOH 10%, the precipitate was filtrated and wash with 3 amount of cold water. The residue was dried to give 112 mg (41%) of white powder.

Abstract

Spermine:peptide-based surfactant compounds are disclosed. The compounds are based on a spermine backbone with peptide groups and optionally hydrocarbyl groups linked thereto. Uses of the spermine:peptide-based surfactant compounds and methods for their production are also disclosed.

Description

  • This invention relates to newly identified spermine:peptide-based surfactant compounds, to the use of such compounds and to processes for their preparation. The invention also relates to the use of the spermine:peptide-based surfactant compounds to facilitate the transfer of compounds into cells for drug delivery.
  • Surfactants are substances that markedly affect the surface properties of a liquid, even at low concentrations. For example surfactants will significantly reduce surface tension when dissolved in water or aqueous solutions and will reduce interfacial tension between two liquids or a liquid and a solid. This property of surfactant molecules has been widely exploited in industry, particularly in the detergent and oil industries. In the 1970s a new class of surfactant molecule was reported, characterised by two hydrophobic chains with polar heads which are linked by a hydrophobic bridge (Deinega, Y et al., Kolloidn. Zh. 36, 649, 1974). These molecules, which have been termed “gemini” (Menger, F M and Littau, C A, J. Am. Chem. Soc. 113, 1451, 1991), have very desirable properties over their monomeric equivalents. For example they are highly effective in reducing interfacial tension between oil and water based liquids and have a very low critical micelle concentration.
  • Cationic surfactants have been used inter alia for the transfection of polynucleotides into cells in culture, and there are examples of such agents available commercially to scientists involved in genetic technologies (for example the reagent Tfx™-50 for the transfection of eukaryotic cells available from Promega Corp. WI, USA).
  • The efficient delivery of DNA to cells in vivo, either for gene therapy or for antisense therapy, has been a major goal for some years. Much attention has concentrated on the use of viruses as delivery vehicles, for example adenoviruses for epithelial cells in the respiratory tract with a view to corrective gene therapy for cystic fibrosis (CF). However, despite some evidence of successful gene transfer in CF patients, the adenovirus route remains problematic due to inflammatory side-effects and limited transient expression of the transferred gene. Several alternative methods for in vivo gene delivery have been investigated, including studies using cationic surfactants. Gao, X et al. (1995) Gene Ther. 2, 710-722 demonstrated the feasibility of this approach with a normal human gene for CF transmembrane conductance regulator (CFTR) into the respiratory epithelium of CF mice using amine carrying cationic lipids. This group followed up with a liposomal CF gene therapy trial which, although only partially successful, demonstrated the potential for this approach in humans (Caplen, N J. et al., Nature Medicine, 1, 3946, 1995). More recently other groups have investigated the potential of other cationic lipids for gene delivery, for example cholesterol derivatives (Oudrhiri, N et al. Proc. Natl. Acad. Sci. 94, 1651-1656, 1997). This limited study demonstrated the ability of these cholesterol based compounds to facilitate the transfer of genes into epithelial cells both in vitro and in vivo, thereby lending support to the validity of this general approach.
  • These studies, and others, show that in this new field of research there is a continuing need to develop novel low-toxicity surfactant molecules to facilitate the effective transfer of polynucleotides into cells both in vitro for transfection in cell-based experimentation and in vivo for gene therapy and antisense treatments. The present invention seeks to overcome the difficulties exhibited by existing compounds.
  • The invention relates to spermine:peptide-based surfactant compounds having a spermine backbone and having the general structure of formula (1):
    Figure US20050089493A1-20050428-C00001

    where R1 and R3 are hydrogen and R2 and R4, which may be the same or different, are peptide groups formed from one or more amino acids linked together, in a linear or branched manner, by amide (CONH) bonds and further linked to the spermine backbone by amide bonds, having the general formula (II):
    Figure US20050089493A1-20050428-C00002

    where p1 is 0 to 5 and p2 is 1 to 5, preferably 1; and the values for p3 and p4, which may be the same or different, are from 0 to 5, preferably 0;
    • A1, A3 and A4, which may be the same or different, are amino acids selected from serine, lysine, ornithine, threonine, histidine, cysteine, arginine and tyrosine; and
    • A2 is an amino acid selected from lysine, ornithine and histidine;
    • and R5 and R6 are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by an amide or an amine (NCH2) linkage; or
    • where R1 and R3 are hydrogen, R2 and R4, which may be the same or different are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by amide or amine bonds, and R5 and R6, which may be the same or different, are peptide groups of formula (11) linked to the spermine backbone by amide bonds; or
    • a salt, preferably a pharmaceutically acceptable salt thereof.
  • When used herein, the term “hydrocarbyl” refers to a group having from 1 to 24 carbon atoms which may be in a straight chain or a branched chain and include a saturated carbocyclic ring having from 3 to 6 carbon atoms and which chain may contain unsaturation (double and/or triple carbon-carbon bonds).
  • The amide linkages between the amino acids A, A2 and A3 in the peptide group of formula (II) are standard peptide bonds (a bonds), unless the amino acid is a diamine, for example lysine or ornithine, where the linkage may involve either of the two amine groups. For example, where A1 is lysine, the linkage to the amino acid A2 may be a standard alpha amide bond, or an epsilon (F) amide bond involving the amine of the lysine side chain. Similarly where A1 is ornithine the amide bond linking A1 to A2 may be an alpha bond or a delta (8) bond that is created using the amine on the side chain of the ornithine amino acid residue.
  • Preferably, the compound is symmetrical, that is R1 and R3 are the same, R2 and R4 are the same, and R5 and R6 are the same. Symmetrical spermine:peptide-based surfactant compounds of the invention are “gemini” surfactants.
  • In a preferred embodiment A1 in the group of formula (II) is serine or threonine, prefereably serine. Preferably A3 and A4 in the group of formula (II) are lysine, ornithine, histidine or arginine.
  • In a further preferred embodiment the hydrocarbyl group is selected from:
    Figure US20050089493A1-20050428-C00003
  • In another preferred embodiment the hydrocarbyl group is selected from:
    • —(CH2)11CH3
    • —(CH2)13CH3
    • —(CH2)15CH3
    • —(CH2)17CH3
    • —(CH2)19CH3
    • —(CH2)23CH3
    • —(CH2)8CH═CH(CH2)5CH3
    • —(CH2)8CH═CH(CH2)7CH3
    • —(CH2)8CH═CHCH2CH═CH(CH2)4CH3
    • —(CH2)8(CH═CHCH2)3CH3
    • —(CH2)4CH═CH(CH2CH═CH)3(CH2)4CH3
    • —(CH2)8CH═CH(CH2)5CH3 Trans
    • —(CH2)8CH═CH(CH2)7CH3 Trans
    • —(CH2)9CHCH3(CH2)7CH3
  • Compounds of the present invention may be prepared from readily available starting materials using synthetic peptide chemistry well known to the skilled person. The scheme shown in FIGS. 1 a and 1 b shows a general process for the synthesis of the compounds of the invention wherein the hydrocarbyl groups are linked to the spermine moiety by amine bonds and the scheme shown in FIGS. 2 a and 2 b shows a general process for the synthesis of the compounds of the invention wherein the carbonyl groups are linked to the spermine moiety by amide bonds.
  • The processes shown in FIGS. 1 and 2 are for the synthesis of symmetrical, that is “gemini”, spermine:peptide-based surfactants. Non-symmetrical spermine:peptide-based surfactants of the invention can be prepared by introducing asymmetry, for example at the primary amines of spermine, by using different protecting groups. Suitable nitrogen protecting groups are well known in the art and are described in, for example, “Protective Groups in Organic Chemistry” (T. W. Greene, Wiley-Interscience, New York, 2nd Edition, 1991).
  • Another aspect of the invention relates to methods for using the spermine:peptide-based surfactant compounds. Such uses include facilitating the transfer of DNA or RNA polynucleotides, or analogs thereof, into a eukaryotic or prokaryotic cell in vivo or in vitro. These uses include facilitating transfection of polynucleotides to achieve an antisense knock-out effect, for gene therapy and genetic immunisation (for the generation of antibodies) in whole organisms. Other uses include employing the compounds of the invention to facilitate the transfection of polynucleotides into cells in culture when such transfer is required, in, for example, gene expression studies and antisense control experiments among others. The polynucleotides can be mixed with the compounds, added to the cells and incubated to allow polynucleotide uptake. After further incubation the cells can be assayed for the phenotypic trait afforded by the transfected DNA, or the levels of mRNA expressed from said DNA can be determined by Northern blotting or by using PCR-based quantitation methods for example the Taqman® method (Perkin Elmer, Connecticut, USA). Compounds of the invention offer a significant improvement, typically between 3 and 6 fold, in the efficiency of cellular uptake of DNA in cells in culture, compared with compounds in the previous art. In the transfection protocol, the gemini compound may be used in combination with one or more supplements to increase the efficiency of transfection. Such supplements may be selected from, for example:
    • (i) a neutral carrier, for example dioleyl phosphatidylethanolamine (DOPE) (Farhood, H., et al (1985) Biochim. Biophys. Acta 1235 289);
    • (ii) a complexing reagent, for example the commercially available PLUS reagent (Life Technologies Inc. Maryland, USA) or peptides, such as polylysine or polyornithine peptides or peptides comprising primarily, but not exclusively, basic amino acids such as lysine, ornithine and/or arginine. The list above is not intended to be exhaustive and other supplements that increase the efficiency of transfection are taken to fall within the scope of the invention.
  • In still another aspect, the invention relates to the transfer of genetic material in gene therapy using the compounds of the invention.
  • Yet another aspect of the invention relates to methods to effect the delivery of non-nucleotide based drug compounds into cells in vitro and in vivo using the compounds of the invention.
  • In a further aspect, the invention relates to methods to facilitate the transfer of a polynucleotide or an anti-infective compounds into prokaryotic or eukaryotic organism for use in anti-infective therapy.
  • The following definitions are provided to facilitate understanding of certain terms used frequently herein.
  • “Amino acid” refers to dipolar ions (zwitterions) of the form +H3NCH(R)CO2—. They are differentiated by the nature of the group R, and when R is different from hydrogen can also be asymmetric, forming D and L families. Amino acids may be natural or un-natural amino acids. There are 20 naturally occurring amino acids where the R group can be, for example, non-polar (e.g. alanine, leucine, phenylalanine) or polar (e.g. glutamic acid, histidine, arginine and lysine). In the case of un-natural amino acids R can be any other group which is not found in the amino acids found in nature.
  • “Polynucleotide” generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or; DNA. “Polynucleotides” include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications have been made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short polynucleotides, often referred to as oligonucleotides.
  • “Transfection” refers to the introduction of polynucleotides into cells in culture using methods involving the modification of the cell membrane either by chemical or physical means. Such methods are described in, for example, Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). The polynucleotides may be linear or circular, single-stranded or double-stranded and may include elements controlling replication of the polynucleotide or expression of homologous or heterologous genes which may comprise part of the polynucleotide.
  • The invention will now be described by way of the following examples.
  • EXAMPLES Example 1 Synthesis of GSC1
  • Step 1:
    Figure US20050089493A1-20050428-C00004
  • A solution of N-carbethoxyphthalimide (4 mmol, 439 mg) in chloroform (5 ml) was added as one portion at room temperature to a stirred solution of spermine (2 mmol, 406.7 mg) in chloroform (5 ml). The mixture was stirred for 1 hour and the solvent was removed, the crude was dried under good vacuum to get the title compound without further purification (Sosnovsky, G. (1986) Zeitschrift für Naturforschung 41b: 122-129).
    Step 2:
    Figure US20050089493A1-20050428-C00005
  • The protected spermine 350 mg (0.76 mmol) was dissolved in 10 ml of dry THF, the Lauroyl chloride 3 eq (2.28 mmol) and 2 ml of dry pyridine was added. After refluxing 30 min, the mixture was stirred at room temperature overnight. Solvent was removed, and the crude was dissolved in AcOEt (25 ml) and was washed with saturated bicarbonate (2×20 ml). The organic phase was dried over anhydrous sodium sulfate and evaporated. The resulting oil was chromatographied on silica gel with AcOEt/hexane (1:1 to 4:1) rf=0.20 (AcOEt/hexane 1:1) to yield 490 mg (84%) of bis-dodecyl as oil which crystallized as white semi-solid crystal. 1H-NMR (CDCl3): 7.9-7.6 m (8H (—C6H4—)2); 3.7-3.6 m (4H); 3.4-3.2 m (8H); 2.3-2.1 m (4H); 2.0-1.8 m (4H); 1.6-1.4 m (8H); 1.3-1.1 m (32H); 0.9-0.8 m (6H). 13C-NMR (CDCl3): 173.1, 173.0, 172.9, 172.8, 168.3, 168.2, 134.2, 134.1, 133.9, 133.8, 132.2, 132.1, 132.0, 131.9, 123.4, 123.2, 47.6, 45.7, 45.5, 45.4, 43.5, 43.4, 35.9, 33.9, 33.2, 33.1, 30.9, 29.6, 29.5, 29.4, 29.3, 29.1, 28.3, 28.2, 27.1, 26.7, 26.4, 25.5, 25.4, 25.2, 25.1, 24.9, 22.7, 14.1.
    Step 3:
    Figure US20050089493A1-20050428-C00006
  • The bis-phthalimide (400 mg, 0.48 mmol) was dissolved in 20 ml of MeOH, hydrazine monohydrate 0.4 ml was added and the mixture was refluxed 6H. Solvent was removed, and the crude redissolved in MeOH (20 ml) and 2 ml of concentrated HCl was added. The mixture was refluxed for 30 min, and solvent was removed. The residue was dissolved in aqueous NaOH 10%, the precipitate was filtrated and wash with 3 amount of cold water. The residue was dried to give 112 mg (41%) of white powder. 1H-NMR (MeOH): 3.21 t (3J=6.8 Hz, 4H); 2.6-2.5 m (8H); 2.76 t (3J=7.5 Hz, 4H); 1.7-1.5 m (12H); 1.4-1.2 m (32H); 0.89 t (3J=6.9 Hz, 6H (—CH3)2).
    Step 4:
    Figure US20050089493A1-20050428-C00007
  • The diamine 100 mg (0.176 mmol), HOBt 2 eq (0.353 mmol, 54 mg), BOC2Lys 2.4 eq (0.423 mmol, 135 mg) and DIPEA 2 eq (0.353 mmol, 62 ml) was dissolved in CH2Cl2 (20 ml). The mixture was cooled at −10° C. and DCC 2.4 eq (0.423 mmol, 87 mg) was added. The mixture was stirred at −10° C. and allowed to reach room temperature very slowly and set aside overnight. The DCU was removed by filtration, and solvent was evaporated off. The crude was redissolved in AcOEt (30 ml), was washed successively 4% NaHCO3 (2×15 ml), 4% citric acid (2×15 ml), water (20 ml) and finally brine (20 ml). Organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness. The residue was chromatographied on silica gel and was eluated with hexane/AcOEt 1/1 (rf=0.01) to AcOEt/MeOH 9/1 (rf=0.6) yield 152 mg (71%) as oil. 1H-NMR (CDCl3): 7.05 sbroad (1H); 6.69 sbroad (1H); 5.6-4.7 m (6H); 4.9-4.1 m (4H); 3.7-3.0 m (16H); 2.2-2.0 m (6H); 2.0-1.0 m (88H); 0.88 t (3J=6.8 Hz, 6H (—CH3)2).
    Step 5:
    Figure US20050089493A1-20050428-C00008
  • The tetra-protected Gemini 150 mg (0.12 mmol) was dissolved in CH2Cl2/TFA 1/1 (25 ml) and was stirred at room temperature for 0.5H. Solvent was removed to give the deprotected compounds as a TFA salt which was exchanged on anionic Dowex 1×8 to get the tetrahydrochloride salt as a sticky oil. The compound was redissolved in small amount of MeOH and precipitate with ether, solvent was removed by decantation, this was repeated three times, to give GSC1. 1H-NMR (MeOH): 3.8-3.1 m (8H); 3.0-2.8 m (4H); 2.2-2.1 m (4H); 2.0-1.4 m (26H); 1.4-1.2 m (36H); 0.90 t (3J=6.8 Hz, 6H (—CH3)2). M/z(H+): 823.75; (2H+): 412.38.
  • Example 2 Synthesis of GSC4
  • Step 1:
    Figure US20050089493A1-20050428-C00009
  • The diamine 150 mg (0.265 mmol) was dissolved in 5% aqueous acetonitrile (10 ml) and triethylamine 2.2 eq (0.6 mmol, 80 μL) was added. The Nα,Nε-bis-ter-butyl-carbamate-L lysine-L-serine-O-succinimidate (was built by the usual peptide synthesis) 2 eq (0.528 mmol, 280 mg) in acetonitrile (8 ml) was added slowly. The mixture was stirred 48H at room temperature, and solvent was removed. The crude was redissolved in AcOEt (30 ml), was washed successively water (2×20 ml), 3% HCl (2×20 ml), water (20 ml) and finally brine (20 ml). Organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness, to yield 252 mg (68%). 1H-NMR (CDCl3): 4.9-4.1 m (4H); 3.6-3.0 m (20H); 2.2-2.0 m (8H); 2.0-1.0 m (80H); 0.88 t (3J=6.8 Hz, 6H (—CH3)2).
    Step 2:
    Figure US20050089493A1-20050428-C00010
  • The tetra-protected Gemini 248 mg (0.177 mmol) was dissolved in THF/HClconc 1/1 (25 ml) and was stirred at room temperature for 1H. Solvent was removed to give the deprotected compounds as a sticky dark oil which was redissolved in small amount of MeOH and precipitate with ether, solvent was removed by decantation, this was repeated several times, to yield 120 mg (60%) GSC4 as pink powder. 1H-NMR (MeOH): 4.0-3.9 m (2H); 3.5-3.2 m; 3.1-2.9 m (4H); 2.5-2.3 m (4H); 2.3-2.1 m (1H); 2.0-1.5 m (20H); 1.4-1.2 m (32H); 0.90 t (3J=6.8 Hz, 6H (—CH3)2).
  • Example 3 Synthesis of GSC40
  • Step 1:
    Figure US20050089493A1-20050428-C00011
  • The diamine 120 mg (0.212 mmol), HOBt 2.5 eq. (0.53 mmol, 72 mg), (BOC2Lys)Lys 2.5 eq. (0.53 mmol, 426 mg) and DIPEA 2.5 eq. (0.53 mmol, 92 μl) was dissolved in CH2Cl2/THF 1/1 (20 ml). The mixture was cooled at −10° C. and DCC 2.4 eq. (0.508 mmol, 105 mg) was added. The mixture was stirred at −10° C. and allowed to reach room temperature very slowly and set aside overnight. The DCU was removed by filtration, and the solvent was evaporated off. The crude product was redissolved in EtOAc (30 ml), was washed successively with 4% NaHCO3 (2×15 ml), 4% citric acid (2×15 ml), water (20 ml) and finally brine (20 ml). the organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness. The residue was chromatographed on silica gel and was eluated with hexane/EtOAc 1/1 (rf=0.01) to EtOAc/MeOH 9/1 (rf=0.55) yield 210 mg (46%) as oil. 1H-NMR (CDCl3): 4.9-4.6 m (2H); 4.1-3.9 m (4H); 3.5-2.9 m (16H); 2.3-2.1 m (2H); 1.9-1.0 m (164H); 0.88 t (3J=6.8 Hz, 6H (—CH3)2).
    Step 2:
    Figure US20050089493A1-20050428-C00012
  • The octa-protected gemini 200 mg (0.094 mmol) was dissolved in THF/HClconc 1/1 (20 ml) and was stirred at room temperature for 1H. The solvent was removed to give the deprotected compounds as a yellow oil which was redissolved in small amount of MeOH and precipitate with ether, the solvent was removed by decantation, this was repeated several times, to yield 130 mg (85%) GSC40 as yellow powder.
  • Example 4 Synthesis of GSC41
  • Step 1:
    Figure US20050089493A1-20050428-C00013
  • The diamine 200 mg (0.35 mmol) was dissolved in 5% aqueous acetonitrile (20 ml) and triethylamine 2 eq. (0.7 mmol, 0.1 ml) was added. The bis-(Nα,Nε-bis-ter-butyl-carbamate-L-lysine)-L-lysine-L-serine-O-succinimidate 2 eq (0.71 mmol, 700 mg) in acetonitrile (10 ml) was added slowly. The mixture was stirred 48 H at room temperature, and solvent was removed. The crude product was redissolved in AcOEt (30 ml), was washed successively water (2×20 ml), 3% HCl (2×20 ml), water (20 ml) and finally brine (20 ml). The organic phase was dried over anhydrous sodium sulfate and was evaporated to dryness, to yield 509 mg (63%). 1H-NMR (CDCl3): 4.9-4.6 m; 4.1-3.9 m (4H); 3.6-2.9 m (22H); 2.3-2.1 m (4H); 2.0-1.0 m; 0.88 t (3J=6.8 Hz, 6H (—CH3)2).
    Step 2:
    Figure US20050089493A1-20050428-C00014
  • The tetra-protected gemini 499 mg (0.216 mmol) was dissolved in THF/HClconc 1/1 (30 ml) and was stirred at room temperature for 1H. the solvent was removed to give the deprotected compounds as a sticky brawn oil which was redissolved in small amount of MeOH and precipitated with ether, solvent was removed by decantation, this was repeated several times, to yield 350 mg (90%) GSC41 as brown powder.
  • Example 5 Synthesis of GSC42
  • Step 1:
    Figure US20050089493A1-20050428-C00015
  • The diamine 200 mg (0.35 mmol) was dissolved in 5% aqueous acetonitrile (20 ml) and triethylamine 2 eq. (0.7 mmol, 0.1 ml) was added. The bis-(Nα,Nε-bis-ter-butyl-carbamate-L-lysine)-L-lysine-L-serine-O-succinimidate 2 eq (0.71 mmol, 700 mg) in acetonitrile (10 ml) was added slowly. The mixture was stirred 48 H at room temperature, and solvent was removed. The crude product was redissolved in AcOEt (30 ml), was washed successively water (2×20 ml), 3% HCl (2×20 ml), water (20 ml) and finally brine (20 ml). The organic phase was dried over anhydrous sodium sulfate and evaporated to dryness, to yield 522 mg (70%). 1H-NMR (CDCl3): 6.7-6.6 m (2H); 5.5-5.3 m (2H); 4.9-4.6 m (4H); 4.54.3 m (4H); 4.1-3.9 m (4H); 3.5-2.9 m (20H); 2.3-2.1 m (4H); 1.9-1.0 m; 0.88 t (3J=6.8 Hz, 6H (—CH3)2).
    Step 2:
    Figure US20050089493A1-20050428-C00016
  • The tetra-protected Gemini 517 mg (0.242 mmol) was dissolved in THF/HClconc 1/1 (30 ml) and was stirred at room temperature for 1H. The solvent was removed to give the deprotected compounds as a sticky dark oil which was redissolved in small amount of MeOH and precipitate with ether, solvent was removed by decantation, this was repeated several times, to yield 346 mg (88%) GSC42 as brown powder.
  • Example 6 Synthesis of GSC2
  • Step 1:
    Figure US20050089493A1-20050428-C00017
  • The protected spermine 1.23 g (2.65 mmol) was dissolved in 1,2-dichloroethane (25 ml) and dodecyl aldehyde 2.5 eq. (6.6 mmol, 1.5 ml) was added. After 10 nm, the sodium cyanoborohydride 6 eq. (15.9 mmol, 1 g) was added and the mixture was stirred at room temperature overnight. Then sodium cyanoborohydide 4.5 eq. (750 mg) was added again and mixture was stirred overnight at room temperature. This solution was partitioned between dichloromethane (150 ml) and water (150 ml) and the pH was adjusted to 9. The resulting emulsion was left in a separating funnel for 12 H. Then, the organic phase was dried over sodium sulfate and concentrated. The crude product was chromatographed on silica gel, eluated with EtOAc/Hexane 1/4 to 1/2 (rf: 0.3) containing 0.1% of NEt3, to yield 540 mg of semi-solid yellow compound (26%).
    Step 2:
    Figure US20050089493A1-20050428-C00018
  • The protected spermine 200 mg (0.25 mmol) was dissolved in methanol (10 ml) and hydrazine monohydrate 10 eq (2.5 mmol, 0.13 ml) was added. The mixture was refluxed for 8H, and the solvent was removed. The crude product was redissolved in 10 ml of methanol and conc. HCl (2 ml) was added, the mixture was refluxed for 30 min, cooled in ice and filtered. The solvent was removed and the crude product redissolved in dichloromethane (30 ml), stirred 30 min at room temperature and the precipate was removed by filtration. The solution was evaporated and dried under reduce pressure to yield 150 mg GSC2 as a yellow semi-solid compound (88%).
  • Example 7 Synthesis of GSC12
  • Step 1:
    Figure US20050089493A1-20050428-C00019
  • The diamine 143 mg (0.265 mmol) was dissolved in 5% aq. THF (10 ml) and NEt3 0.6 mmol (80 ml), activated peptide 2 eq (0.528 mmol, 282 mg) in THF (5 ml) were added. The mixture was stirred overnight and concentrated. Then, the crude product was dissolved in EtOAc (60 ml) and was washed successively with water (2×20 ml) 3% HCl (2×20 ml) water (20 ml) brine (20 ml). The organic phase was dried over sodium sulfate and the solvent was evaporated to yield 210 mg of a sticky white compound (58%).
    Step 2:
    Figure US20050089493A1-20050428-C00020
  • The tetra-Boc 200 mg (0.146 mmol) was dissolved in THF/conc. HCl 1/1 (20 ml) and was stirred at room temperature for 1H. The solvent was removed and the crude product was redissolved in small amount of MeOH and precipitated with ether, cooled to −20° C., the solvent was removed by decantation, this was repeated several times, to yield 150 mg (87%) GSC12 as a yellow powder.
  • Example 8 Transfection of Recombinant Plasmid Expressing Luciferase into Cells using Spermine:Peptide-Based Surfactant Compounds
  • Transfection studies were performed using the adherent cell line CHO-K1 (Puck et al. 1958). Complete medium consisted of MEM alpha medium supplemented with 10% v/v foetal bovine serum and 1×L-Glutamine. All media and supplements were obtained from Life Technologies.
  • Stable transfected cell lines expressing β-galactosidase were generated by cotransfection of the plasmid pSV-β-Galactosidase Control Vector (Promega) with the plasmid Selecta Vecta-Neo (R & D Systems) in a 10:1 ratio. Following G418 (Life Technologies) selection (0.8 mg ml−1); candidate cell lines were tested for β-galactosidase activity (β-Gal Reporter Gene Assay, chemiluminescent; Roche Diagnostics).
  • In Vitro Gene Transfection.
  • Cells were seeded into 96-well MTP plates (Beckton Dickinson) 16-18 hours prior to transfection at an approximate density of 1×104 cells per well. For transfection, 64 ng of the luciferase reporter gene plasmid, pGL3-Control Vector (Promega) per well, was incubated with various concentrations of the spermine:peptide-based surfactant compounds and complexing agents. After 30 minutes incubation at RT, OPTI-MEM® medium (Life Technologies) was added to the transfection mixture and the solution placed on the cells (final volume per well: 100 μl). Following a 3 hour or over night incubation at 37° C., the transfection solution was replaced with complete medium and the cells incubated further at 37° C. Reporter gene assays were performed according to the manufacturer's guidelines (Roche Diagnostics) approximately 48 hours post transfection. Luminescence was measured in a Packard TopCount NXT Microplate Scintillation and Luminescence Counter. For normalization purpose, β-galactosidase activity (β-Gal Reporter Gene Assay, chemiluminescent; Roche Diagnostics) was measured and luciferase activity per β-galactosidase activity was calculated.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 a and FIG. 1 b. General sheme for synthesis of spermine:peptide-based surfactant compounds wherein the carbonyl groups (in this instance dodecanoyl) are linked to the spermine moiety by amide bonds. The final compound in FIG. 1 a is the first compound in FIG. 1 b.
  • FIG. 2 a and FIG. 2 b. General sheme for synthesis of spermine:peptide-based 110 surfactant compounds wherein the carbonyl groups (in this instance dodecanoyl) are linked to the spermine moiety by amine bonds. The final compound in FIG. 2 a is the first compound in FIG. 2 b.
  • FIG. 3. Transfection of CHO-K1 cells (stable transfected with beta-galactosidase) with spermine:peptide-based gemini surfactants GS-C-1, GS-C-2, GS-C-3, GS-C-4 and GS-C-12. Bars represent the mean cps (counts per second) of 8 experiments±the standard error of the mean.

Claims (33)

1. A spermine:peptide-based surfactant compound having the general structure of formula (1):
Figure US20050089493A1-20050428-C00021
where R1 and R3 are hydrogen and R2 and R4, which may be the same or different, are peptide groups formed from one or more amino acids linked together, in a linear or branched manner, by amide (CONH) bonds and further linked to the spermine backbone by amide bonds, having the general formula (II):
Figure US20050089493A1-20050428-C00022
where
p1 is 0 to 5 and p2 is 1 to 5; and the values for p3 and p4, which may be the same or different, are from 0 to 5;
A1, A3 and A4, which may be the same or different, are amino acids selected from serine, lysine, ornithine, threonine, histidine, cysteine, arginine and tyrosine; and
A2 is an amino acid selected from lysine, ornithine and histidine;
and R5 and R6 are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by an amide or an amine (NCH2) linkage; or
where R1 and R3 are hydrogen, R2 and R4, which may be the same or different are saturated or unsaturated hydrocarbyl groups having up to 24 carbon atoms and linked to the spermine backbone by amide or amine bonds, and R5 and R6, which may be the same or different, are peptide groups of formula (II) linked to the spermine backbone by amide bonds; or
a salt, preferably a pharmaceutically acceptable salt thereof.
2. A spermine:peptide-based surfactant compound according to claim 1 which is symmmetrical, that is R1 and R3 are the same, R2 and R4 are the same, and R5 and R6 are the same.
3. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (I) p1 is 1 and p2, p3 and p4 are all 0.
4. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (11)p1 and p2 are both 1 and p3 and p4 are both 0.
5. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (I) p1 is 0 and p2, p3 and p4 are all 1.
6. A spermine:peptide-based surfactant compound according to claim 1 or 2 wherein in the peptide group of formula (I) p1 and p3 are 0, p2 is 1 and p4 is 2.
7. A spermine:peptide-based surfactant compound according to any one of claims 1 to 6 wherein the A1 is serine.
8. A spermine:peptide-based surfactant compound according to any one of claims 1 to 6 wherein the A2 is lysine.
9. A spermine:peptide-based surfactant compound according to claim 1 wherein the hydrocarbyl group is selected from:
—(CH2)11CH3
—(CH2)13CH3
—(CH2)15CH3
—(CH2)17CH3
—(CH2)19CH3
—(CH2)23CH3
—(CH2)8CH═CH(CH2)5CH3
—(CH2)8CH═CH(CH2)7CH3
—(CH2)8CH═CHCH2CH═CH(CH2)4CH3
—(CH2)8(CH═CHCH2)3CH3
—(CH2)4CH═CH(CH2CH═CH)3(CH2)4CH3
—(CH2)8CH═CH(CH2)5CH3 Trans
—(CH2)8CH═CH(CH2)7CH3 Trans
—(CH2)9CHCH3(CH2)7CH3
10. A spermine:peptide-based surfactant compound according to claim 1 wherein the hydrocarbyl group is selected from:
—CO(CH2)10CH3
—CO(CH2)12CH3
—CO(CH2)14CH3
—CO(CH2)16CH3
—CO(CH2)18CH3
—CO(CH2)22CH3
—CO(CH2)7CH═CH(CH2)5CH3
—CO(CH2)7CH═CH(CH2)7CH3
—CO(CH2)7CH═CHCH2CH═CH(CH2)4CH3
—CO(CH2)7(CH═CHCH2)3CH3
—CO(CH2)3CH═CH(CH2CH═CH)3(CH2)4CH3
—CO(CH2)7CH═CH(CH2)5CH3 Trans
—CO(CH2)7CH═CH(CH2)7CH3 Trans
—CO(CH2)8CHCH3(CH2)7CH3
—COCHOH(CH2)21CH3
Figure US20050089493A1-20050428-C00023
11. The compound:
Figure US20050089493A1-20050428-C00024
12. The compound:
Figure US20050089493A1-20050428-C00025
13. The compound GSC1 of formula:
Figure US20050089493A1-20050428-C00026
14. The compound GSC4 of formula:
Figure US20050089493A1-20050428-C00027
15. The compound GSC40 of formula:
Figure US20050089493A1-20050428-C00028
16. The compound GSC42 of formula:
Figure US20050089493A1-20050428-C00029
17. The compound GSC2 of formula:
Figure US20050089493A1-20050428-C00030
18. The compound GSC12 of formula:
Figure US20050089493A1-20050428-C00031
19. The use of a spermine:peptide-based surfactant compound as defined in any one of claims 1 to 15 in facilitating transfection of DNA or RNA polynucleotides or analogs thereof into a eukaryotic or prokaryotic cell in vivo or in vitro.
20. The use of a spermine:peptide-based surfactant compound according to claim 19 wherein the compound is used in combination with one or more supplements selected from the group consisting of:
(i) a neutral carrier; or
(ii) a complexing reagent.
21. The use according to claim 20 wherein the neutral carrier is dioleoyl phosphatidylethanolamine (DOPE).
22. The use according to claim 20 wherein the complexing reagent is PLUS reagent.
23. The use according to claim 20 wherein the complexing reagent is a peptide comprising mainly basic amino acids.
24. The use according to claim 23 wherein the peptide consists of basic amino acids.
25. The use according to claim 23 or 24 wherein the basic amino acids are selected from lysine and arginine.
26. The use according to claim 24 wherein the peptide is polylysine or polyornithine.
27. The use according to any one of claims 19 to 26 wherein the oligonucleotides or polynucleotides are transferred into cells to achieve an antisense knock-out effect.
28. The use according to claim 19 wherein the oligonucleotides or polynucleotides are transferred into cells for gene therapy.
29. The use according to claim 19 wherein the oligonucleotides or polynucleotides are transferred into cells for genetic immunisation (for the generation of antibodies) in whole organisms.
30. The use according to any one of claims 19 to 26 wherein the oligonucleotides or polynucleotides are transferred into cells in culture.
31. The use of a spermine:peptide-based surfactant compound of any one of claims 1 to 18 to facilitate the transfer of a polynucleotide or an anti-infective compounds into prokaryotic or eukaryotic organism for use in anti-infective therapy.
32. The use of a spermine:peptide-based surfactant compound of any one of claims 1 to 18 to facilitate the adhesion of cells in culture to each other or to a solid or semi-solid surface.
33. A process for preparing spermine:peptide-based surfactant compounds of claim 1 which process comprises adding amino acids or peptides to a hydrocarbylated spermine backbone.
US10/990,819 1999-06-16 2004-11-17 Novel compounds Abandoned US20050089493A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/990,819 US20050089493A1 (en) 1999-06-16 2004-11-17 Novel compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9914045.1A GB9914045D0 (en) 1999-06-16 1999-06-16 Novel compounds
GB9914045.1 1999-06-16
US10/018,547 US6835712B1 (en) 1999-06-16 2000-06-16 Compounds
PCT/GB2000/002364 WO2000077032A2 (en) 1999-06-16 2000-06-16 Spermine:peptide-based surfactant compounds
US10/990,819 US20050089493A1 (en) 1999-06-16 2004-11-17 Novel compounds

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2000/002364 Division WO2000077032A2 (en) 1999-06-16 2000-06-16 Spermine:peptide-based surfactant compounds
US10/018,547 Division US6835712B1 (en) 1999-06-16 2000-06-16 Compounds

Publications (1)

Publication Number Publication Date
US20050089493A1 true US20050089493A1 (en) 2005-04-28

Family

ID=10855486

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/018,547 Expired - Lifetime US6835712B1 (en) 1999-06-16 2000-06-16 Compounds
US10/990,819 Abandoned US20050089493A1 (en) 1999-06-16 2004-11-17 Novel compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/018,547 Expired - Lifetime US6835712B1 (en) 1999-06-16 2000-06-16 Compounds

Country Status (9)

Country Link
US (2) US6835712B1 (en)
EP (1) EP1187806B1 (en)
JP (1) JP4759193B2 (en)
AT (1) ATE349419T1 (en)
AU (1) AU5690400A (en)
DE (1) DE60032600T2 (en)
ES (1) ES2278618T3 (en)
GB (1) GB9914045D0 (en)
WO (1) WO2000077032A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093973A1 (en) * 2007-02-27 2010-04-15 Ajinomoto Co., Inc. Poly(amino acid) compound having inhibitory activity on absorption of phosphorus and phosphorus absorption inhibitor

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914045D0 (en) * 1999-06-16 1999-08-18 Smithkline Beecham Plc Novel compounds
JP2005529860A (en) * 2002-03-27 2005-10-06 グラクソ グループ リミテッド Gemini surfactant compounds based on diamino acids-amino acids-polyamines
GB0425556D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0425555D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0502482D0 (en) * 2005-02-07 2005-03-16 Glaxo Group Ltd Novel compounds
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
CA2665225C (en) * 2006-10-03 2015-06-30 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
CN102941160A (en) * 2012-12-13 2013-02-27 贵州大学 Flotation collector for silicate minerals
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6835712B1 (en) * 1999-06-16 2004-12-28 Smithkline Beecham P.L.C. Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6117542A (en) * 1984-07-03 1986-01-25 Takeda Chem Ind Ltd Spermine derivative
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
NZ313839A (en) * 1995-07-21 1998-12-23 Genta Inc Amide-based cationic lipids
FR2741066B1 (en) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS
GB9726073D0 (en) * 1997-12-09 1998-02-04 Smithkline Beecham Plc Novel compounds
EP1129064B1 (en) * 1998-11-12 2008-01-09 Invitrogen Corporation Transfection reagents
GB9929712D0 (en) 1999-12-17 2000-02-09 Berman Jeffrey Improvements to digital media cases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6835712B1 (en) * 1999-06-16 2004-12-28 Smithkline Beecham P.L.C. Compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093973A1 (en) * 2007-02-27 2010-04-15 Ajinomoto Co., Inc. Poly(amino acid) compound having inhibitory activity on absorption of phosphorus and phosphorus absorption inhibitor

Also Published As

Publication number Publication date
GB9914045D0 (en) 1999-08-18
US6835712B1 (en) 2004-12-28
JP2003504311A (en) 2003-02-04
EP1187806A2 (en) 2002-03-20
ATE349419T1 (en) 2007-01-15
WO2000077032A3 (en) 2001-05-31
JP4759193B2 (en) 2011-08-31
WO2000077032A2 (en) 2000-12-21
ES2278618T3 (en) 2007-08-16
AU5690400A (en) 2001-01-02
DE60032600T2 (en) 2007-05-03
DE60032600D1 (en) 2007-02-08
EP1187806B1 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
AU707947B2 (en) Novel amide-based cationic lipids
US7425645B2 (en) Ester-linked gemini surfactant compounds for use in gene therapy
US6638529B2 (en) Amide-based cationic lipids
EP0830368A1 (en) Novel carbamate-based cationic lipids
US6835712B1 (en) Compounds
US6693167B1 (en) Peptide-based gemini compounds
AU745958B2 (en) Novel lipopolyamines, and the preparation and use thereof
US20030119188A1 (en) Novel compounds
JP4990154B2 (en) Amide and peptide derivatives of tetraalkylenepentamine as transfection agents
US20060148734A1 (en) Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
US20040138139A1 (en) Novel compounds
US20080234464A1 (en) Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same
ES2391098T3 (en) Derivatives of amides and peptides of dialkylenetriamines and their use as transfection agents
US7005300B1 (en) Polyhydroxy diamine surfactants and their use in gene transfer

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION